Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
Open accessThe DOI matches its Crossref record; 83 of the 86 references it cites were found in a registry or an index.
Abstract
The RAS gene family is among the most studied and best characterized of the known cancer-related genes. Of the three human ras isoforms, KRAS is the most frequently altered gene, with mutations occurring in 17%–25% of all cancers. In particular, approximately 30%–40% of colon cancers harbor a KRAS mutation. KRAS mutations in colon cancers have been associated with poorer survival and increased tumor aggressiveness. Additionally, KRAS mutations in colorectal cancer lead to resistance to select treatment strategies. In this review we examine the history of KRAS, its prognostic value in patients with colorectal cancer, and evidence supporting its predictive value in determining appropriate therapies for patients with colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, the epidermal growth factor receptor (EGFR)/RAS/MAPK signaling pathway is often constitutively activated, either through activation of signaling proteins RAS (KRAS mutated in ~40% of CRCs) or RAF (BRAF mutated in 10–15% of CRCs), which stimulates cell proliferation [13,14,15].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [15]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728 · cited 2×
“Since only 30%–50% of colorectal cancers have KRAS mutations [4,18,21], there has been speculation that the detection of KRAS mutation may portend a worse prognosis.”
BackgroundHuman microRNA genes are frequently located at fragile sites and genomic regions involved in cancers
Calin, G. A., Sevignani, C., Dumitru, C. D., Hyslop, T., Noch, E., Yendamuri, S., Shimizu, M., Rattan, S., Bullrich, F., Negrini, M., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307323101 · Cited by 4,095 · cited 1×
“addition, miRNA expression is often lost in cancer because they tend to be located in genomic regions that are frequently lost during cancer development [67].”
BackgroundCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 2×
“Similarly, 6% (60 of 999) of tumor samples in the CRYSTAL study had a BRAF mutation, mainly in the setting of wild-type KRAS [44,45].”
BackgroundResultRAS Is Regulated by the let-7 MicroRNA Family
Johnson, S. M., Grosshans, H., Shingara, J., Byrom, M., Jarvis, R., Cheng, A., Labourier, E., Reinert, K. L., Brown, D., & Slack, F. J. (2005) · Cell · doi:10.1016/j.cell.2005.01.014 · Cited by 3,656 · cited 4×
“The reduced expression of let-7 in cancer tissues corresponds to significantly higher levels of KRAS mRNA [70].”
BackgroundInfluentialK-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · cited 1×
“anti-EGFR monoclonal antibodies cetuximab or panitumumab [47,48].”
Non-coding RNAs and cancer: microRNAs and beyond
Raia, R. M., & Calin, G. A. (2011) · Journal of Nucleic Acids Investigation · doi:10.4081/jnai.2011.e5 · Cited by 3,382
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“anti-EGFR monoclonal antibodies cetuximab or panitumumab [47,48].”
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690 · cited 1×
“Given that EGFR, a transmembrane receptor tyrosine kinase, is overexpressed in 25%–75% of colorectal tumors [38,39], a significant proportion of patients that may benefit from anti-EGFR agents may also have KRAS mutation.”
BackgroundChemotherapy with Preoperative Radiotherapy in Rectal Cancer
Bosset, J.-F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., Daban, A., Bardet, E., Beny, A., & Ollier, J.-C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060829 · Cited by 2,688
Research works printed but not linked: 3
- Louvet, 2001, Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma, Cancer, 91, 2033, 10.1002/1097-0142(20010601)91:11<2033::aid-cncr1229>3.0.co;2-j · DOI · Paper page
- Goldstein, 2001, Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: Implications for a standardized scoring system, Cancer, 92, 1331, 10.1002/1097-0142(20010901)92:5<1331::aid-cncr1455>3.0.co;2-m · DOI · Paper page
- Mayer, 1993, The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer, Cancer, 71, 2454, 10.1002/1097-0142(19930415)71:8<2454::aid-cncr2820710805>3.0.co;2-2 · DOI · Paper page
Cited by
Biomarkers in Cancer Detection, Diagnosis, and Prognosis
Das, S., Dey, M. K., Devireddy, R., & Gartia, M. R. (2023) · Sensors · doi:10.3390/s24010037 · Cited by 383
Sullivan, R. J., Infante, J. R., Janku, F., Wong, D. J. L., Sosman, J. A., Keedy, V., Patel, M. R., Shapiro, G. I., Mier, J. W., Tolcher, A. W., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1119 · Cited by 426
“Anemia 0 (0) 1 (20) 0 (0) 0 (0) 6 (5) 5 (4) 0 (0) 3 (27) 15 (11)”
Self-citationBedard, P. L., Tabernero, J., Janku, F., Wainberg, Z. A., Paz-Ares, L., Vansteenkiste, J., Van Cutsem, E., Pérez-García, J., Stathis, A., Britten, C. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1814 · Cited by 324
Cancer Diagnosis: From Tumor to Liquid Biopsy and Beyond
Vaidyanathan, R., Soon, R. H., Zhang, P., Jiang, K., & Lim, C. T. (2018) · Lab on a Chip · doi:10.1039/c8lc00684a · Cited by 259
Pathological Features and Prognostication in Colorectal Cancer
Chen, K., Collins, G., Wang, H., & Toh, J. W. T. (2021) · Current Oncology · doi:10.3390/curroncol28060447 · Cited by 242
“KRAS mutations contribute to unregulated cell growth, ultimately leading to the expansion of tumour cell growth [85,86].”
Background
Metadata
- Authors
- Arrington, A. K., Heinrich, E. L., Lee, W., Duldulao, M., Patel, S., Sanchez, J., Garcia-Aguilar, J., & Kim, J.
- Affiliations
- City Of Hope National Medical Center (US)
- University of Southern California (US)
- Division of Colorectal Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 11597, USA
- Corresponding author
- Arrington, Amanda K.
- Kim, Joseph
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2012-09-25
- Volume
- 13
- Issue
- 10
- Pages
- 12153-12168
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC3497263
- OpenAlex
- W1991898744
- Cited by
- 244
- References
- 86
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 18 · 2023: 20 · 2022: 16 · 2021: 28 · 2020: 29 · 2019: 22 · 2018: 10 · 2017: 13 · 2016: 14 · 2015: 15 · 2014: 20 · 2013: 8
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Keywords
- KRAS mutation, colorectal cancer, prognostic factors, predictive biomarkers, ras gene family, treatment resistance, tumor aggressiveness, survival
- MeSH terms
- Humans, Polymorphism, Genetic, Prognosis, Colorectal Neoplasms, ras Proteins, MicroRNAs, Proto-Oncogene Proteins B-raf, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer. https://app.cochat.ai/papers/10.3390/ijms131012153
- The paper
- Arrington, A. K., Heinrich, E. L., Lee, W., Duldulao, M., Patel, S., Sanchez, J., Garcia-Aguilar, J., & Kim, J. (2012). Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms131012153
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


